173 related articles for article (PubMed ID: 27578038)
1. A systematic review of breath analysis and detection of volatile organic compounds in COPD.
Christiansen A; Davidsen JR; Titlestad I; Vestbo J; Baumbach J
J Breath Res; 2016 Aug; 10(3):034002. PubMed ID: 27578038
[TBL] [Abstract][Full Text] [Related]
2. Observation of nonanoic acid and aldehydes in exhaled breath of patients with lung cancer.
Callol-Sanchez L; Munoz-Lucas MA; Gomez-Martin O; Maldonado-Sanz JA; Civera-Tejuca C; Gutierrez-Ortega C; Rodriguez-Trigo G; Jareno-Esteban J
J Breath Res; 2017 Apr; 11(2):026004. PubMed ID: 28440225
[TBL] [Abstract][Full Text] [Related]
3. Exhaled breath profiling in patients with COPD and OSA overlap syndrome: a pilot study.
Dragonieri S; Quaranta VN; Carratu P; Ranieri T; Resta O
J Breath Res; 2016 Nov; 10(4):041001. PubMed ID: 27811380
[TBL] [Abstract][Full Text] [Related]
4. Exhaled volatile organic compounds discriminate patients with chronic obstructive pulmonary disease from healthy subjects.
Besa V; Teschler H; Kurth I; Khan AM; Zarogoulidis P; Baumbach JI; Sommerwerck U; Freitag L; Darwiche K
Int J Chron Obstruct Pulmon Dis; 2015; 10():399-406. PubMed ID: 25759572
[TBL] [Abstract][Full Text] [Related]
5. External validation of exhaled breath profiling using an electronic nose in the discrimination of asthma with fixed airways obstruction and chronic obstructive pulmonary disease.
Fens N; Roldaan AC; van der Schee MP; Boksem RJ; Zwinderman AH; Bel EH; Sterk PJ
Clin Exp Allergy; 2011 Oct; 41(10):1371-8. PubMed ID: 21732998
[TBL] [Abstract][Full Text] [Related]
6. A dual center study to compare breath volatile organic compounds from smokers and non-smokers with and without COPD.
Gaida A; Holz O; Nell C; Schuchardt S; Lavae-Mokhtari B; Kruse L; Boas U; Langejuergen J; Allers M; Zimmermann S; Vogelmeier C; Koczulla AR; Hohlfeld JM
J Breath Res; 2016 Apr; 10(2):026006. PubMed ID: 27082437
[TBL] [Abstract][Full Text] [Related]
7. Exhaled breath profiling enables discrimination of chronic obstructive pulmonary disease and asthma.
Fens N; Zwinderman AH; van der Schee MP; de Nijs SB; Dijkers E; Roldaan AC; Cheung D; Bel EH; Sterk PJ
Am J Respir Crit Care Med; 2009 Dec; 180(11):1076-82. PubMed ID: 19713445
[TBL] [Abstract][Full Text] [Related]
8. Machine learning methods on exhaled volatile organic compounds for distinguishing COPD patients from healthy controls.
Phillips CO; Syed Y; Parthaláin NM; Zwiggelaar R; Claypole TC; Lewis KE
J Breath Res; 2012 Sep; 6(3):036003. PubMed ID: 22759349
[TBL] [Abstract][Full Text] [Related]
9. Methodology validation, intra-subject reproducibility and stability of exhaled volatile organic compounds.
Basanta M; Ibrahim B; Douce D; Morris M; Woodcock A; Fowler SJ
J Breath Res; 2012 Jun; 6(2):026002. PubMed ID: 22549110
[TBL] [Abstract][Full Text] [Related]
10. Breath profiles by electronic nose correlate with systemic markers but not ozone response.
Biller H; Holz O; Windt H; Koch W; Müller M; Jörres RA; Krug N; Hohlfeld JM
Respir Med; 2011 Sep; 105(9):1352-63. PubMed ID: 21439804
[TBL] [Abstract][Full Text] [Related]
11. A profile of volatile organic compounds in breath discriminates COPD patients from controls.
Van Berkel JJ; Dallinga JW; Möller GM; Godschalk RW; Moonen EJ; Wouters EF; Van Schooten FJ
Respir Med; 2010 Apr; 104(4):557-63. PubMed ID: 19906520
[TBL] [Abstract][Full Text] [Related]
12. An electronic nose in the discrimination of patients with non-small cell lung cancer and COPD.
Dragonieri S; Annema JT; Schot R; van der Schee MP; Spanevello A; Carratú P; Resta O; Rabe KF; Sterk PJ
Lung Cancer; 2009 May; 64(2):166-70. PubMed ID: 18834643
[TBL] [Abstract][Full Text] [Related]
13. Clinical use of exhaled volatile organic compounds in pulmonary diseases: a systematic review.
van de Kant KD; van der Sande LJ; Jöbsis Q; van Schayck OC; Dompeling E
Respir Res; 2012 Dec; 13(1):117. PubMed ID: 23259710
[TBL] [Abstract][Full Text] [Related]
14. Study of 5 Volatile Organic Compounds in Exhaled Breath in Chronic Obstructive Pulmonary Disease.
Jareño-Esteban JJ; Muñoz-Lucas MÁ; Gómez-Martín Ó; Utrilla-Trigo S; Gutiérrez-Ortega C; Aguilar-Ros A; Collado-Yurrita L; Callol-Sánchez LM
Arch Bronconeumol; 2017 May; 53(5):251-256. PubMed ID: 27780574
[TBL] [Abstract][Full Text] [Related]
15. Discrimination between COPD patients with and without alpha 1-antitrypsin deficiency using an electronic nose.
Hattesohl AD; Jörres RA; Dressel H; Schmid S; Vogelmeier C; Greulich T; Noeske S; Bals R; Koczulla AR
Respirology; 2011 Nov; 16(8):1258-64. PubMed ID: 21883674
[TBL] [Abstract][Full Text] [Related]
16. Exhaled breath condensate biomarkers in COPD.
Borrill ZL; Roy K; Singh D
Eur Respir J; 2008 Aug; 32(2):472-86. PubMed ID: 18669788
[TBL] [Abstract][Full Text] [Related]
17. Measurement of exhaled volatile organic compounds from patients with chronic obstructive pulmonary disease (COPD) using closed gas loop GC-IMS and GC-APCI-MS.
Allers M; Langejuergen J; Gaida A; Holz O; Schuchardt S; Hohlfeld JM; Zimmermann S
J Breath Res; 2016 Apr; 10(2):026004. PubMed ID: 27058460
[TBL] [Abstract][Full Text] [Related]
18. Exhaled volatile organic compounds for phenotyping chronic obstructive pulmonary disease: a cross-sectional study.
Basanta M; Ibrahim B; Dockry R; Douce D; Morris M; Singh D; Woodcock A; Fowler SJ
Respir Res; 2012 Aug; 13(1):72. PubMed ID: 22916684
[TBL] [Abstract][Full Text] [Related]
19. Do linear logistic model analyses of volatile biomarkers in exhaled breath of cystic fibrosis patients reliably indicate Pseudomonas aeruginosa infection?
Španěl P; Sovová K; Dryahina K; Doušová T; Dřevínek P; Smith D
J Breath Res; 2016 Aug; 10(3):036013. PubMed ID: 27532768
[TBL] [Abstract][Full Text] [Related]
20. Can exhaled volatile organic compounds predict asthma exacerbations in children?
van Vliet D; Smolinska A; Jöbsis Q; Rosias P; Muris J; Dallinga J; Dompeling E; van Schooten FJ
J Breath Res; 2017 Mar; 11(1):016016. PubMed ID: 28102830
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
